The hepatitis C virus -- HCV -- can persist in the livers of those infected and even lead to liver disease or failure in extreme cases. It affects tens of millions of people worldwide and there is no vaccine to prevent infection, but effective treatment can resolve most cases.

Until about a decade ago, hepatitis C infection was difficult to cure because treatment relied on prolonged interferon injections with severe side effects. The advent of oral direct-acting antivirals, or DAAs, revolutionized care for HCV. However, whether clearing HCV would also alleviate chronic immune activation remained uncertain, especially in people living with human immunodeficiency virus, or HIV, whose immune systems are already under strain.

This uncertainty is exacerbated by inequalities in research and care across international borders. Previous research on the immunological effects of DAAs has largely originated from the Global North and involved patients from those regions. None existed from Southeast Asia where viral strains, methods of transmission, host genetics, and access to care differ. This motivated a collaborative team of researchers from Kyoto University and the University of Indonesia to address this knowledge gap.

Two new Cochrane reviews show strong and consistent evidence that HPV vaccines are effective in preventing cervical cancer and pre-cancerous changes, especially when given to young people before they are exposed to the virus.